EA200201011A1 - Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5 - Google Patents

Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5

Info

Publication number
EA200201011A1
EA200201011A1 EA200201011A EA200201011A EA200201011A1 EA 200201011 A1 EA200201011 A1 EA 200201011A1 EA 200201011 A EA200201011 A EA 200201011A EA 200201011 A EA200201011 A EA 200201011A EA 200201011 A1 EA200201011 A1 EA 200201011A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pde5
dysfunction
erektile
pde5 inhibitor
phosphodiesterase
Prior art date
Application number
EA200201011A
Other languages
English (en)
Inventor
Джон С. Уайтейкер
Иниго Саэнс Де Техада
Кеннет М. Фергьюсон
Original Assignee
ЛИЛЛИ АЙКОС эЛ-эЛ-Си
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЛИЛЛИ АЙКОС эЛ-эЛ-Си filed Critical ЛИЛЛИ АЙКОС эЛ-эЛ-Си
Publication of EA200201011A1 publication Critical patent/EA200201011A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к ингибиторам фермента фосфодиэстеразы (ФДЭ) и к их использованию в фармацевтических изделиях. В частности, данное изобретение относится к сильнодействующим ингибиторам циклической гуанозин 3',5'-монофосфат специфичной фосфодиэстеразы 5-го типа (ФДЭ5), которая при введении в фармацевтический продукт в разовой дозированной лекарственной форме от около 1 до около 10 мг является полезной для лечения половой дисфункции посредством ежедневного введения ингибитора ФДЭ5. Промышленные изделия, описанные в этом изобретении, характеризуются ингибированием ФДЭ5 и, таким образом, приносят выгоду в тех областях терапии, в которых ингибирование ФДЭ5 является желательным, особенно эректильной дисфункции, с минимизированием или устранением неблагоприятных побочных эффектов, получающихся от ингибирования других ферментов фосфодиэстеразы, и с улучшением васкулярного состояния.Отчет о международном поиске был опубликован 2002.06.06.
EA200201011A 2000-04-26 2001-04-13 Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5 EA200201011A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/558,911 US6451807B1 (en) 1999-04-30 2000-04-26 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
PCT/US2001/012512 WO2001080860A2 (en) 2000-04-26 2001-04-13 Daily treatment for erectile dysfunction using a pde5 inhibitor

Publications (1)

Publication Number Publication Date
EA200201011A1 true EA200201011A1 (ru) 2003-06-26

Family

ID=24231497

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201011A EA200201011A1 (ru) 2000-04-26 2001-04-13 Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5

Country Status (20)

Country Link
US (2) US6451807B1 (ru)
EP (1) EP1276481A2 (ru)
JP (1) JP2003531174A (ru)
KR (1) KR20030007551A (ru)
CN (1) CN1446091A (ru)
AU (1) AU2001253612A1 (ru)
BR (1) BR0110373A (ru)
CA (1) CA2407519A1 (ru)
CZ (1) CZ20023577A3 (ru)
EA (1) EA200201011A1 (ru)
HR (1) HRP20020827A2 (ru)
HU (1) HUP0300477A3 (ru)
IL (1) IL152227A0 (ru)
MX (1) MXPA02010539A (ru)
NO (1) NO20025138L (ru)
NZ (1) NZ521869A (ru)
PL (1) PL360186A1 (ru)
SK (1) SK15392002A3 (ru)
WO (1) WO2001080860A2 (ru)
ZA (1) ZA200208776B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
AU2001257146B2 (en) * 2000-04-19 2006-11-30 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
CN101106997A (zh) * 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7265248B1 (en) 2005-04-29 2007-09-04 Technology Innovations, Llc Compositions and methods for the treatment of malaria
WO2007100387A2 (en) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Process for preparing tadalafil
US20100324037A1 (en) * 2006-08-24 2010-12-23 Surface Logix, Inc. Pharmacokinetically improved compounds
TWI462923B (zh) * 2010-10-18 2014-12-01 Univ Kaohsiung Medical Kmup-3之心肌梗塞疾患用途
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
JP6578046B1 (ja) * 2018-08-23 2019-09-18 Towa Corporation 株式会社 Pde5阻害用医薬組成物及びpde5阻害用食品組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931445A (en) 1988-10-06 1990-06-05 Irwin Goldstein Agents for treatment of male impotence
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
EP1038963B1 (en) 1993-05-27 2009-08-05 Board Of Regents Of The University Of Washington Cyclic GMP-binding, cyclic GMP-specific phosphodiesterase materials and methods
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
IL126951A0 (en) 1996-05-10 1999-09-22 Icos Corp Carboline derivatives
CA2339630C (en) 1998-09-16 2006-05-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors

Also Published As

Publication number Publication date
SK15392002A3 (sk) 2003-03-04
MXPA02010539A (es) 2003-05-14
NZ521869A (en) 2004-10-29
BR0110373A (pt) 2003-02-18
KR20030007551A (ko) 2003-01-23
CA2407519A1 (en) 2001-11-01
WO2001080860A3 (en) 2002-06-06
NO20025138L (no) 2002-12-16
IL152227A0 (en) 2003-05-29
CN1446091A (zh) 2003-10-01
US20030100478A1 (en) 2003-05-29
NO20025138D0 (no) 2002-10-25
AU2001253612A1 (en) 2001-11-07
PL360186A1 (en) 2004-09-06
US6451807B1 (en) 2002-09-17
ZA200208776B (en) 2003-06-03
CZ20023577A3 (cs) 2003-06-18
HUP0300477A3 (en) 2004-10-28
EP1276481A2 (en) 2003-01-22
WO2001080860A2 (en) 2001-11-01
JP2003531174A (ja) 2003-10-21
HUP0300477A2 (hu) 2003-06-28
HRP20020827A2 (en) 2004-12-31

Similar Documents

Publication Publication Date Title
EA200000355A2 (ru) Промышленные изделия
EA200201011A1 (ru) Ежедневное лечение эректильной дисфункции с использованием ингибитора фдэ5
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction